Jared Silverman joined the Bill & Melinda Gates Medical Research Institute in January 2018 as Head of Translational Discovery.
He was previously Senior Vice President of Research at Kaleido Biosciences, responsible for building a drug discovery pipeline to identify novel modulators of the human microbiome to treat and prevent disease.
Jared’s whole career has focused on the discovery and development of novel antibiotics to treat serious drug resistant infections in hospitals.
Before Kaledio, Jared spent 18 years at Cubist Pharmaceuticals, including five years as Vice President of Discovery Biology. There he contributed to the discovery of three novel antibiotics that entered clinical development, including Surotomycin, currently in phase III trials for the treatment of C. difficile. With internal and external collaborators, he has also conducted research into the mechanisms of action and resistance to the lipopeptide antibiotic daptomycin.
Jared has authored nearly 50 papers and holds multiple patents. He has been a member of the National Institutes of Health Drug Discovery and Resistance study section, is an editor at Antimicrobial Agents and Chemotherapy, and a member of the Medical Research Council steering committee for antimicrobial resistance.
Jared received his undergraduate degree in molecular biology from Princeton, his PhD in microbiology from Harvard University and completed his postdoctoral training at Yale University before joining Cubist in 1997.